Biodistribution and dosimetry of (iodine-123)-iodomethyl-N,N-diethyltamoxifen, an (anti)oestrogen receptor radioligand

European Journal of Nuclear Medicine

Volumn 26, Issue 10, 1999, Pages 1259-1264

  Van de Wiele, C ^a   De Vos, F ^b   De Sutter, J ^a   Dumont, F ^b   Slegers, G ^b   Dierckx, R A ^a   Thierens, H ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Breast carcinoma; Iodomethyl N,N diethyltamoxifen; Therapeutic efficacy

Indexed keywords

ANTIESTROGEN; IODINE 123; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN DERIVATIVE;

ADULT; ARTICLE; BLADDER WALL; BLOOD ANALYSIS; BRAIN; BREAST; BREAST CARCINOMA; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TUMOR LEVEL; FEMALE; GALLBLADDER; HEART; HEPATOBILIARY SYSTEM; HUMAN; HUMAN EXPERIMENT; IMAGING; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; LIVER; NORMAL HUMAN; THYROID GLAND; URINALYSIS; WHOLE BODY SCINTISCANNING;

ABDOMEN; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MIDDLE AGED; POSTMENOPAUSE; RADIOPHARMACEUTICALS; RECEPTORS, ESTROGEN; TAMOXIFEN; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 0032879165     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050581     Document Type: Article

References (27)

1. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990; 11: 221-265.
2. Henderson IC. Endocrine therapy in metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast diseases. Philadelphia: Lippincott; PA, 1987: 398-428.
3. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978; 5:428-433.
4. Horwitz KB, Wei LL, Sedlack SM, d'Arville CN. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res 1985; 41: 249-316.
5. Alexieva-Figusch J, Van Putten WLJ, Blankenstein MA, Blonk-van der Wijst J, Klijn JGM. The prognostic value and relationships of patient characteristics, progestin receptor, oestrogen receptor, and site of relapse in primary and metastatic human breast cancer. Cancer 1988; 61: 758-768.
6. Klijn JGM, Berns EMJJ, Lambert CJ, Dorssers J, Foekens JA. Molecular markers of resistance to endocrine treatment of breast cancer. In: Dickson RB, Lippman ME, eds. Drug and hormonal resistance in breast cancer: cellular and molecular mechanisms. Hertfordshire, UK: Ellis Horwood; 1995: 133-168.
7. Klijn JGM. Clinical parameters and symptoms for the progression to endocrine independence or breast cancer. In: Berns PMJJ, Romijn JC, Schröder FH, eds. Mechanisms of progression to hormone-independent growth of breast and prostatic cancer. Carnforth: Parthenon; 1991: 11-19.
8. Horwitz KB. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat 1993; 26: 119-130.
9. Pink JJ, Jordan VC. Molecular mechanisms of antiestrogen resistance. In Dickson RB, Lippman ME, eds. Drug and hormonal resistance in breast cancer: cellular and molecular mechanisms., Hertfordshire, UK: Ellis Horwood; 1995: 95-113.
10. Wiebe VJ, DeGregorio MW, Osborne CK. Tamoxifen metabolism and resistance. In Dickson RB, Lippman ME, eds. Drug and hormonal resistance in bresat cancer: cellular and molecular mechanisms. Hertfordshire, UK: Ellis Horwood; 1995: 115-131.
11. Yang DJ, Tewson T, Tansey W et al. Halogenated analogues of tamoxifen: synthesis, receptor assay and inhibition of MCF-7 cells. J Pharm Sci. 1992; 81: 622-625.
12. Yang DJ, Chun L, Kuang LR et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Science 1994; 55: 53-67.
13. Cherif A, Delpassand ES, Wallace S, Cromeens D, Zareneyri F, Podoloff DA, Yang DJ. Radiosynthesis of tamoxifen analogues for imaging endometrial disease. J Labelled Compd Radiopharm 1996; 60: 338-340.
14. Hidalgo JU, Nadler SB, Bloch T. The use of electronic digital computer to determine best fit of blood volume formulas. J Nucl Med 1962; 3: 94.
15. Cloutier R, Smith S, Watson E, Snyder W, Warner G. Dose to the fetus from radionuclides in the bladder. Health Phys 1973; 25: 147-161.
16. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP Publication 30. New York: Pergamon Press, 1979.
17. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. New York: Society of Nuclear Medicine, 1988.
18. Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photon sources. ORNL/TM-8381/VII. Oak Ridge, Tenn: Oak Ridge National Laboratory; 1987: 7-29.
19. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
20. Shani J, Gazit A, Livshitz T, Brian S. Synthesis and receptor binding affinity of fluorotamoxifen, a possible oestrogen-receptor imaging agent. J Med Chem 1985; 28: 1504-1511.
21. Kangas L, Nieminen AL, Blanco G et al. A new triphenylethylene compound, Fc-1157a II. Antitumour effect. Cancer Chemother Pharmacol 1986; 17: 103-108.
22. Kallio S, Kangas L, Blanco G et al. A new triphenylethylene compound, Fc-1157a II. Hormonal effect. Cancer Chemother Pharmacol 1986; 17: 103-108.
23. Erlichman C, Loprinzi CL. Hormonal therapies. In: DeVita VT Jr, Hellman S, rosenberg SA, eds. Cancer principles and practice of oncology. Philadelphia: Lippincott-Raven; 1997: 395-405.
24. International Commission on Radiological Protection. 1990 recommendations of the International Commission on Radiological Protection 60. New York: Pergamon Press, 1991.
25. Beekhuis H. Population radiation absorbed dose from nuclear medicine procedures in The Netherlands. Health Phys 1988; 54: 287-291.
26. World Health Organisation Technical Report Series 611. Use of ionizing radiation and radionuclides on human beings for medical research, training, and non-medical purposes. Report of a WHO expert Committee. Geneva: WHO, 1977.
27. Annals of the ICRP. Radiological protection in biomedical research. New York: Pergamon Press, 1991: 12-13.